BIOMAT Database Logo BIOMAT Database Logo

A2B adenosine receptor antagonists: recent developments. 2005

Barbara Cacciari, and Giorgia Pastorin, and Chiara Bolcato, and Giampiero Spalluto, and Magdalena Bacilieri, and Stefano Moro
Dipartimento di Scienze Farmaceutiche, Università degli Studi di Trieste, Piazzale Europa 1, I-34127 Trieste, Italy.

There are pharmacological evidences that A(2B) receptors are involved in inflammatory processes, such as asthma. For this reason, many efforts has been made for identifying selective A(2B) antagonists as anti-asthmatic agents. The updated material related to this field has been rationalised and arranged in order to offer an overview of the topic.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D011799 Quinazolines A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring. Quinazoline
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000893 Anti-Inflammatory Agents Substances that reduce or suppress INFLAMMATION. Anti-Inflammatory Agent,Antiinflammatory Agent,Agents, Anti-Inflammatory,Agents, Antiinflammatory,Anti-Inflammatories,Antiinflammatories,Antiinflammatory Agents,Agent, Anti-Inflammatory,Agent, Antiinflammatory,Agents, Anti Inflammatory,Anti Inflammatories,Anti Inflammatory Agent,Anti Inflammatory Agents
D001249 Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL). Asthma, Bronchial,Bronchial Asthma,Asthmas
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D014230 Triazoles Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3. Triazole
D014970 Xanthines Purine bases found in body tissues and fluids and in some plants.

Related Publications

Barbara Cacciari, and Giorgia Pastorin, and Chiara Bolcato, and Giampiero Spalluto, and Magdalena Bacilieri, and Stefano Moro
Recent developments in A2B adenosine receptor ligands.
January 2009, Handbook of experimental pharmacology,
Barbara Cacciari, and Giorgia Pastorin, and Chiara Bolcato, and Giampiero Spalluto, and Magdalena Bacilieri, and Stefano Moro
Irreversible Antagonists for the Adenosine A2B Receptor.
June 2022, Molecules (Basel, Switzerland),
Barbara Cacciari, and Giorgia Pastorin, and Chiara Bolcato, and Giampiero Spalluto, and Magdalena Bacilieri, and Stefano Moro
A2B Adenosine Receptor Antagonists with Picomolar Potency.
April 2019, Journal of medicinal chemistry,
Barbara Cacciari, and Giorgia Pastorin, and Chiara Bolcato, and Giampiero Spalluto, and Magdalena Bacilieri, and Stefano Moro
Antinociceptive effects of novel A2B adenosine receptor antagonists.
January 2004, The Journal of pharmacology and experimental therapeutics,
Barbara Cacciari, and Giorgia Pastorin, and Chiara Bolcato, and Giampiero Spalluto, and Magdalena Bacilieri, and Stefano Moro
[Advances in the study of A2B adenosine receptor antagonists].
March 2008, Yao xue xue bao = Acta pharmaceutica Sinica,
Barbara Cacciari, and Giorgia Pastorin, and Chiara Bolcato, and Giampiero Spalluto, and Magdalena Bacilieri, and Stefano Moro
Recent developments in the field of A2A and A3 adenosine receptor antagonists.
April 2003, European journal of medicinal chemistry,
Barbara Cacciari, and Giorgia Pastorin, and Chiara Bolcato, and Giampiero Spalluto, and Magdalena Bacilieri, and Stefano Moro
New pyrrolopyrimidin-6-yl benzenesulfonamides: potent A2B adenosine receptor antagonists.
July 2006, Bioorganic & medicinal chemistry letters,
Barbara Cacciari, and Giorgia Pastorin, and Chiara Bolcato, and Giampiero Spalluto, and Magdalena Bacilieri, and Stefano Moro
A patent review of adenosine A2B receptor antagonists (2016-present).
June 2022, Expert opinion on therapeutic patents,
Barbara Cacciari, and Giorgia Pastorin, and Chiara Bolcato, and Giampiero Spalluto, and Magdalena Bacilieri, and Stefano Moro
Mu opioid receptor antagonists: recent developments.
November 2007, ChemMedChem,
Barbara Cacciari, and Giorgia Pastorin, and Chiara Bolcato, and Giampiero Spalluto, and Magdalena Bacilieri, and Stefano Moro
Recent Developments in Androgen Receptor Antagonists.
November 2015, Archiv der Pharmazie,
Copied contents to your clipboard!